Positive Inotropic drugs Mechanism Dosage Drug Interactions Precautions Chemical Properties Uses production method
ChemicalBook > CAS DataBase List > Milrinone

Milrinone

Positive Inotropic drugs Mechanism Dosage Drug Interactions Precautions Chemical Properties Uses production method
Product Name
Milrinone
CAS No.
78415-72-2
Chemical Name
Milrinone
Synonyms
YM-018;Milrila;Primacor;Corotrop;win47203;Corotrope;MILRINONE;Milirinone;Milrinonee;PriMacor IV
CBNumber
CB8695411
Molecular Formula
C12H9N3O
Formula Weight
211.22
MOL File
78415-72-2.mol
More
Less

Milrinone Property

Melting point:
>3000C
Boiling point:
350.9°C (rough estimate)
Density 
1.1922 (rough estimate)
refractive index 
1.5700 (estimate)
storage temp. 
2-8°C
solubility 
DMSO: >10 mg/mL
form 
powder
pka
7.21±0.10(Predicted)
color 
off-white
Water Solubility 
Soluble in DMSO. Insoluble in water.
Merck 
14,6197
Stability:
Stable. Incompatible with strong oxidizing agents.
InChIKey
FYEJSUDMDUIMKJ-UHFFFAOYSA-N
CAS DataBase Reference
78415-72-2(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
T,T+
Risk Statements 
23/24/25-26/27/28
Safety Statements 
36/37/39-45-22
RIDADR 
UN 2811 6.1/PG 3
WGK Germany 
3
RTECS 
DW1762000
HazardClass 
6.1(b)
PackingGroup 
III
HS Code 
29337900
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H300Fatal if swallowed

H301Toxic if swalloed

H311Toxic in contact with skin

H331Toxic if inhaled

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P304+P340IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.

P405Store locked up.

P403+P233Store in a well-ventilated place. Keep container tightly closed.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
PHR2515
Product name
Milrinone
Purity
Pharmaceutical Secondary Standard; Certified Reference Material
Packaging
1G
Price
$249
Updated
2021/12/16
Sigma-Aldrich
Product number
475840
Product name
Milrinone
Packaging
10mg
Price
$249.75
Updated
2021/12/16
Sigma-Aldrich
Product number
1443908
Product name
Milrinone
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
500mg
Price
$612
Updated
2021/12/16
Sigma-Aldrich
Product number
M4659
Product name
Milrinone
Purity
≥97% (TLC), powder
Packaging
10mg
Price
$259
Updated
2021/03/22
Sigma-Aldrich
Product number
M4659
Product name
Milrinone
Purity
≥97% (TLC), powder
Packaging
50mg
Price
$825
Updated
2021/03/22
More
Less

Milrinone Chemical Properties,Usage,Production

Positive Inotropic drugs

Milrinone, also known as bipyridine ketone, methyl cyanide topiramate ketone, is a drug for the treatment of heart failure ,it is a homolog of amrinone, having positive inotropic and vasodilatory effects, its mechanism of action is the same as ammonia milrinone , but the strength of its effect is 10 to 30 times of amrinone,without side effects of reducing platelets,it is well tolerated. Oral or intravenous way has a good effect, it can increase cardiac output and cardiac index, reduce left ventricular end diastolic pressure, pulmonary wedge pressure and right atrial pressure, it has no significant effect on blood pressure and heart rate,it takes effect within 0.5 hours after oral administration,and achieves to maximum effect after 1 to 3 hours , the half-life is 2 hours, the effect can be maintained for 4-6 hours, it is mainly metabolically inactivated in the liver , 80% of it is excreted unchanged in the urine. It is clinically used in the treatment of various acute and chronic heart failure,it is effective in digitalis and diuretics invalid refractory heart failure . This product is the same as amrinone, significant short-term effect, long-term efficacy remains to be further confirmed, but the side effects are little.
Compared with amrinone, milrinone has the following characteristics:
1, small doses mainly have positive inotropic effect, vasodilator effect is gradually enhanced while increasing the dose ,its positive inotropic effect accounts for 1/3 of the total effect in the treatment of heart failure, vasodilation effect accounts for2/3 of the total effect.
2,not significantly increasing myocardial oxygen consumption.
3, to improve peripheral circulatory disorders in heart failure, to increase exercise capacity of patients with heart failure and improve their quality of life.
4, for cardiac β receptors in a low-key and reduced β agonistssusceptibility heart failure patients, the drug is still valid.
5, the positive inotropic effect does not produce tachyphylaxis phenomenon.
6, no significant effect on blood pressure and heart rate.
The above information is edited by the Chemicalbook of Tian Ye.

Mechanism

Milrinone is non-digitalis, non-catecholamines cardiac drug , it is representative drug of phosphodiesterase inhibitor,selectively inhibiting phosphodiesterase in myocardial cells, increasing intracellular cyclic adenosine monophosphate, alter intracellular calcium transport, thereby increasing myocardial contractility and expanding peripheral vessel . An increase in myocardial oxygen consumption caused by Milrinone increasing myocardial contractility may be offset by its vasodilator effect. Milrinone is an ideal drug for the treatment of coronary artery stenosis, decompensated heart failure led by myocardial ischemia . Because milrinone hasβ receptor down features, it is an ideal drug for the treatment of decompensated heart failure in patients applying β-blocker . Because milrinone has effect on expanding small arteries and veins, it is more beneficial than dobutamine for the traetment of decompensated heart failure with severe pulmonary hypertension .

Dosage

First dose is slow intravenous injection (50 μg/kg, intravenous injection after dilution, time is not less than 10 min), then with 0.375~0.750 μg/(kg · min), continuous intravenous drip. The maximum daily dose is 1.13 mg/kg. Patients with renal insufficiency reduce the use according to creatinine clearance level, for example, creatinine clearance rate is 20 ml/(min · 1.73 m2), intravenously at a dose of 0.28 μg/(kg · min). 80% of Milrinone is excreted from the kidneys, in general,for renal insufficiency patients, the dose should be halved.

Drug Interactions

Patients already receiving angiotensin-converting enzyme inhibitor therapy using milrinone can further improve hemodynamics, but also increase the side effects caused by the blood vessels dilation. Milrinone combinated with mid-dose dobutamine, can enhance the positive inotropic effect, further reducing left ventricular end-diastolic pressure. When there is low blood pressure, milrinone can theoretically combine a larger dose dopamine.

Precautions

1, showing ventricular arrhythmia, supraventricular arrhythmias; few are headache, ventricular arrhythmias, weakness, low platelet count, etc; overdose may lead to low blood pressure, tachycardia; occasionally bronchospasm, fever .
2, acute myocardial infarction patients are disabled.
3, patients with hypotension, tachycardia, renal insufficiency, atrial fibrillation or flutter, electrolyte imbalance, drug-induced arrhythmias, kidney disease, severe aortic or pulmonary valve disease , pregnant women, lactating women should use with caution.
4,the elimination half-life of this product is significantly prolonged in patients with renal insufficiency , it should be reduced in patients with renal insufficiency, and the infusion rate should be slow . Elderly patients do not need to adjust the dose.

Chemical Properties

Crystallization From Dimethyl formamide monohydrate or ethanol, the melting point> 300 ℃.

Uses

New non-glycosides non-catecholamines cardiac drug , its function is similar to amrinone ,positive inotropic effect is strong and about 20 to 50 times of amrinone, and it has significant effect on expanding smooth muscle,it can reduce the load on the heart, it can also improve kidney and muscle blood supply. Oral and intravenous are valid, no serious adverse reactions. It is used For severe heart failure such as chronic heart failure and congestive heart failure.

production method

Method 1: 4-methylpyridine is dissolved in anhydrous diethyl ether, under protection of nitrogen, a solution of phenyl lithium in diethyl ether is added dropwise with stirring at room temperature, the reaction is continued. Nitrogen is stopped, cool to 0 ℃, ethyl acetate is added dropwise at below 10 ℃. With concentrated hydrochloric acid to Ph = 1~2, the aqueous layer is separated, basify with saturated sodium carbonate to Ph = 9, precipitate oil , extract several times with chloroform, dry, chloroform is distilled off, vacuum distillation, collecting 130-132 ℃/1.47kPa of fractions, namely, 1-(4-pyridyl) acetone.
1-(4-pyridyl) acetone, acetonitrile, and N, N-dimethylformamide dimethyl acetal are refluxed together. The solvent is distilled off under reduced pressure, the residue is dissolved in an appropriate amount of chloroform and an alumina column (Soxhlet)is heated at reflux for extraction, concentrate extract, with carbon tetrachloride-cyclohexane (4: 1) recrystallize to give 1-(4-pyridyl)-2-(dimethylamino) ethenyl methyl ketone.
1-(4-pyridyl)-2-(dimethylamino) ethenyl methyl ketone, cyano acetamide, sodium methoxide and dimethyl formamide are heated under reflux, the solvent is distilled off under reduced pressure, the residue is added acetonitrile, warm to dissolve , cool to 10 ℃; the precipitated solid is filtered, dissolve with amount of water, decolorize with charcoal, and acidify with hydrochloric acid 6mol/L to Ph = 6.5~7, the precipitated solid is recrystallized from dimethylformamide to give pale yellow granular crystals, which are milrinone, mp> 300 ℃.
Method 2: use 4-pyridyl acetone as a raw material, after condensation with triethyl orthoformate, it reacts with 2-cyanoacetamide, to obtain milrinone.
Method 3: pyridyl acetone reacts with 2,2-cyano-vinyl ethyl ether reaction to generate milrinone.

Description

Milrinone, an inhibitor of phosphodiesterase selective for fraction III PDE, exerts a positive inotropic effect on the heart as well as a peripheral vasodilatory effect. Milrinone given intravenously produces significant improvements on cardiac output, pulmonary capillary wedge pressure and vascular resistance without significant effects on the heart rate.

Description

Milrinone is an inhibitor of type 3 phosphodiesterases (PDEs), inhibiting recombinant PDE3A and PDE3B with IC50 values of 0.45 and 1 μM, respectively. It is selective for PDE3 over PDE1, PDE2, PDE4, PDE5, and PDE7 (IC50s = 263, >300, 17.5, 49.1, and 58.3 μM, respectively). Milrinone (0.1-1 mg/kg) has positive inotropic effects, increasing cardiac contractile force in anesthetized dogs with a concomitant increase in heart rate but not blood pressure. It also increases contractile force in models of propranolol- and verapamil-induced heart failure in anesthetized dogs when administered at an initial dose of 30 μg/kg followed by a continuous 3 μg/kg per minute infusion. Milrinone has vasodilatory effects as well, decreasing mean aortic pressure and increasing venous compliance in anesthetized dogs when administered at an initial dose of 10 μg/kg followed by a continuous 1.7-2.4 μg/kg per minute infusion. Formulations containing milrinone have been used in the treatment of heart failure.

Chemical Properties

Crystalline Solid

Originator

Eastman Kodak (Sterling) (USA)

Uses

antidepressant, 5HT reuptake inhibitor

Uses

bronchodilator

Uses

Selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity. Cardiotonic

Uses

It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in cAMP levels leads to increased activation of protein kinase A. It is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity.

Manufacturing Process

A mixture containing 20 g of 1-(4-pyridinyl)-2-propanone and 30 ml ofhexamethylphosphoramide was diluted with 65 ml of dimethylformamidedimethyl acetal and the resulting mixture was refluxed for 30 min. TLCanalysis showed a single spot, thereby indicating completion of the reaction(in another run, the reaction appeared to be complete after 30 min at roomtemperature). The mixture was evaporated under reduced pressure and apressure, thereby resulting in a crystalline residue weighing 24 g. The residuewas purified by continuous chromatographic extraction on alumina (about 150g) using refluxing chloroform as eluant. After 90 min, the extract was heatedin vacuo to remove the chloroform, thereby leaving, as a light yellowcrystalline material, 23.2 g of 1-(4-pyridinyl)-2-(dimethylamino)ethenylmethyl ketone, alternatively named 4-dimethylamino-2-(4-pyridinyl)-3-buten-2-one.
To a mixture containing 23 g of 1-(4-pyridinyl)-2-(dimethylamino)ethenylmethyl ketone and 11 g of α-cyanoacetamide dissolved in 400 ml ofdimethylformamide was added with stirring 14 g of sodium methoxide and theresulting reaction mixture was heated in an oil bath under gentle reflux forone hour. TLC analysis showed no starting material in the reaction mixturewhich was then concentrated in vacuo on a rotary evaporator to a volume ofabout 80 ml. The concentrate was treated with about 160 ml of acetonitrileand the resulting mixture was stirred on a rotary evaporator with warminguntil homogenous and then cooled. The crystalline product was collected,rinsed successively with acetonitrile and ether, and dried overnight at 55°C toyield 28 g of crystalline product, namely, sodium salt of 1,2-dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile, the presence of cyano being confirmed byIR analysis. An 8 g portion of said sodium salt was dissolved in 75 ml of hotwater, the aqueous solution treated with decolorizing charcoal, filtered, thefiltrate again treated with decolorizing charcoal and filtered, and the filtrateacidified with 6 N hydrochloric acid by dropwise addition to a pH of 3. Theacidic mixture was diluted with ethanol and cooled. The crystalline productwas collected, dried, recrystallized from dimethylformamide-water and dried toproduce 3.75 g of 1,2-dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile,m.p. >300°C.
Another method of preparation of 1,2-dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile (Patent US 4,413,127)
A 69.5 g portion of 1-ethoxy-2-(4-pyridinyl)ethenyl methyl ketone wasdissolved in 300 ml of ethanol and to the solution was added 13.2 g ofmalononitrile. The resulting mixture was refluxed for 5 hours, crystals startingto separate after about 30 min of refluxing. The reaction mixture was allowedto cool to room temperature and, the precipitate of fine needles was filtered,washed with ethanol and dried in a vacuum at 90°C to yield 25.4 g of 1,2-dihydro-6-methyl-2-oxo-5-(4-pyridinyl)-nicotinonitrile, m.p. >300°C.Concentration of the mother liquor provided another 2.1 g of product, m.p.>300°C.
To a aqueous solution of 1,2-dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile was added one molar equivalent of lactic acid to prepare themonolactate of 1,2-dihydro-6-methyl-2-oxo-5-(4-pyridinyl)nicotinonitrile.

brand name

Primacor (Sterling Winthrop);Corotrope.

Therapeutic Function

Cardiotonic

General Description

Milrinone, 1,6-dihydro-2-methyl-6-oxo-3,4'-bipyridine-5-carbonitrile (Primacor), is another dipyridinephosphodiesterase F-III inhibitor that possesses pharmacologicalproperties similar to those of amrinone. The inhibitionof the degradation of cAMP results in an increase in the cardiacmuscle’s force of contraction.

Biological Activity

Potent cAMP phosphodiesterase inhibitor (IC 50 = 56 nM for inhibition of PDE III). Has inotropic and vasodilator effects following oral or intravenous administration in vivo . Also available as part of the Phosphodiesterase Inhibitor Tocriset™ .

More
Less

Milrinone Suppliers

Wuhan Biocause Pharmaceutical Development Co., Ltd..
Tel
027-84222527
Fax
027-84222392
Email
zb_911@163.com
Country
China
ProdList
11
Advantage
58
Suzhou Huihe Pharmaceutical Co. Ltd.
Tel
86-0512-88819360/88985990
Fax
86-0512-86876095
Email
asynderm@163.com
Country
China
ProdList
90
Advantage
60
Changzhou Chenhong Biotechnology Co., Ltd.
Tel
0519-85788828
Email
sales@chemrenpharm.com
Country
China
ProdList
3134
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833- ;010-82848833
Fax
86-10-82849933
Email
jkinfo@jkchemical.com;market6@jkchemical.com
Country
China
ProdList
96815
Advantage
76
3B Pharmachem (Wuhan) International Co.,Ltd.
Tel
821-50328103-801
Fax
86-21-50328109
Email
3bsc@sina.com
Country
China
ProdList
15877
Advantage
69
Chembest Research Laboratories Limited
Tel
021-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
5947
Advantage
61
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386 / 800-988-0390
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24555
Advantage
81
Energy Chemical
Tel
021-58432009
Fax
021-58436166
Email
sales8178@energy-chemical.com
Country
China
ProdList
43432
Advantage
61
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078;021-50426030
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
10006
Advantage
60
Pure Chemistry Scientific Inc.
Tel
001-857-928-2050 or 1-888-588-9418
Fax
001-617-206-9595
Email
sales@chemreagents.com
Country
United States
ProdList
9917
Advantage
62
More
Less

View Lastest Price from Milrinone manufacturers

WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Product
Milrinone 78415-72-2
Price
US $0.00/KG
Min. Order
100g
Purity
98%+
Supply Ability
100kg
Release date
2020-11-04
Hebei Lingding Biological Technology Co., Ltd
Product
Milrinone 78415-72-2
Price
US $350.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
9000kg/per week
Release date
2021-10-29
WUHAN FORTUNA CHEMICAL CO., LTD
Product
Milrinone 78415-72-2
Price
US $0.00/Kg/Bag
Min. Order
10g
Purity
98%-102% HPLC; USP
Supply Ability
1000G
Release date
2021-07-20

78415-72-2, MilrinoneRelated Search:


  • Corotrope
  • Milrila
  • 3-CYANO-6-METHYL-5-(4-PYRIDYL)-2-PYRIDONE
  • 6-METHYL-5-(4-PYRIDYL)-2-PYRIDONE-3-CARBONITRILE
  • 1,6-DIHYDRO-2-METHYL-6-OXO-(3,4'-BIPYRIDINE)-5-CARBONITRILE
  • Primacor
  • 6-Methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
  • YM-018
  • 2-Oxo-5-(4-pyridyl)-6-methyl-1,2-dihydropyridine-3-carbonitrile
  • 3-Cyano-5-(4-pyridyl)-6-methyl-2(1H)-pyridone
  • Milrinone,97%
  • Milrinone,1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile
  • Milrinone (500 mg)
  • 6-Methyl-2-oxo-5-(pyridin-4-yl)piperidine-3-carbonitrile
  • [3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-Methyl-6-oxo-
  • 2-Methyl-6-oxo-1,6-dihydro-[3,4']bipyridinyl-5-carbonitrile
  • Milrinone(PriMacor)
  • Milrinone API
  • Corotrop
  • 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone
  • PriMacor IV
  • Milrinone USP
  • 1,6-DIHYDRO-2-METHYL-6-OXO-3,4-BIPYRIDINE-5-CARBONITRILE
  • 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)-NICOTINONITRILE
  • MILRINONE
  • 4’-bipyridine)-5-carbonitrile,1,6-dihydro-2-methyl-6-oxo-(
  • win47203
  • Milirinone
  • MilrinoneUsDmf
  • 2-METHYL-6-OXO-1,6-DIHYDRO-3,4'-BIPYRIDINE-5-CARBONITRILE(MILRINONE)
  • 1,2-DIHYDRO-6-METHYL-2-OXO-5-(4-PYRIDINYL)- NICOTINONITRILES(MILRINONE)
  • 6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile
  • MILKTHISTLEP.E
  • 1,2-Dihydro-6-methyl-2-oxo-5-pyridin-4-ylnicotinonitrile
  • Milrinone,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile
  • Milrinone, >=99%
  • Milrinone Injection
  • Milrinone - CAS 78415-72-2 - Calbiochem
  • Milrinone Milrinone
  • Milrinone&gt
  • 2-Methyl-6-oxo-1,6-dihydro-[3,4'-bipyridine]-5-carbonitrile
  • Milrinone USP/EP/BP
  • Milrinonee
  • Milrinone (Win47203
  • 78415-72-2
  • 74815-72-2
  • C12H9N3O
  • Phosphodiesterase Inhibitors
  • G Proteins and Cyclic Nucleotides
  • Cyclic Nucleotide Metabolism
  • Cell Biology
  • Cell Signaling and Neuroscience
  • BioChemical
  • Cyclic Nucleotide related
  • Pharmaceutical Intermediate
  • Pharmaceuticals
  • Pyridines
  • Heterocycles